|
[1]Day CP.Nonalcoholic steatohepatitis (NASH) :where are we nowand where are we going?[J].Gut, 2002, 50∶585-588.
|
|
[2]Marchesini G, Forlani G.NASH:from liver diseases to metabolicdisorders and back to clinical hepatology[J].Hepatology, 2002, 35∶497-499.
|
|
[3]范建高, 丁晓东, 曾说.非酒精性脂肪性肝炎:美国肝脏病学会专题研讨会纪要[J].肝脏, 2003, 8 (2) ∶59-61.
|
|
[4]朱曼, 王睿, 张永清, 等.大鼠肝微粒体细胞色素P450酶系检测方法学研究[J].中国临床药理学与治疗学, 2004, 9 (5) ∶500-503.
|
|
[5]尤鹏.非酒精性脂肪肝炎发病机制的研究进展[J].中国医药导刊, 2003, 5 (2) ∶97-99.
|
|
[6]Rashid A, Wu T, Huang C, et al.Mitochondrial proteins that regu-late apoptosis and necrosis are induced in mouse fatty liver[J].Hep-atology, 1999, 29∶1131-1138.
|
|
[7]Bugianesi E, Manzini P, D'Antico S, et al.Relative contribution ofiron burden, HFE mutations, and insulin resistance to fibrosis innonalcoholic fatty liver[J].Hepatology, 2004, 39∶179-187.
|
|
[8]Rao MS, Reddy JK.Peroxisomal beta-oxidation and steatohepatitis[J].Semin Liver Dis, 2001, 21 (1) ∶43-55.
|